Sector News

Loaded up with debt from M&A binge, Valeant still needs more deals

June 23, 2015
Life sciences
Things appear to be going pretty smoothly for serial dealmaker Valeant since its failed bid for Allergan in November. The Canadian pharma bounced back with two deals earlier this year and is rumored to have another one in the works, helping it deliver on its goal of expanding into high-growth markets to become one of the world’s top-5 drugmakers by 2016.
 
But Valeant’s M&A binge could be taking its toll on the company, even as it continues to ink new deals and score points with investors. As Bloomberg reports, the Laval, Quebec-based company has largely relied on debt to fuel its deal-making engine, bringing the amount of money it owes banks and bondholders to 6.6 times what it earned before interest, taxes, depreciation and amortization in the past 12 months. For comparison’s sake, the average Standard & Poor’s 500 company is half as indebted, the Bloomberg article notes.
 
“Valeant’s entire story is: Buy something, gut it, get a one-time boost from firing everybody, jack up prices on products and then go buy something else,” Gimme Credit analyst Vicki Bryan told the news outlet. “It buys low-quality assets, overpays substantially for them and loads up with debt to do it.”
 
Still, Valeant’s New York-listed stock has shot up 94% in the past 12 months–its best rolling 12-month performance since it was founded in 2010–and its bonds are outperforming the broader high-yield market, according to Bank of America Merill Lynch Indexes seen by Bloomberg. Many analysts are counting on the company’s avid dealmaking strategy to keep its train chugging along, despite its failure to win Allergan.
 
That failed deal was “a disappointment for Valeant management,” Morningstar analyst Michael Waterhouse told the news outlet. But “there’s still a lot of opportunity for this company to find attractive deals, so there’s probably a pretty long runway left,” he added. Valeant in February snatched up prostate cancer vaccine Provenge from bankrupt Dendreon for $400 million to expand its footprint in oncology. The Canadian pharma snatched up Salix Pharmaceuticals the same month for $10.1 billion, grabbing a piece of the fast-growing GI market.
 
But Valeant is also setting its sights abroad, reportedly eyeing an $800 million deal for one of Egypt’s largest drugmakers, Amoun, to beef up in developing countries. And if CEO J. Michael Pearson has his way, the deals will keep flowing in the 2015, bringing the company one step closer to hitting its ambitious growth targets.
 
“We are continuing to focus on building diversified, durable businesses with strong organic growth platforms and pursuing disciplined business development opportunities,” Laurie Little, Valeant spokeswoman, told Bloomberg. “With 2015 off to a strong start, we are well positioned for another year of outperformance.”
 
By Emily Wasserman
 

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend